

Ex. I

2 DISTRICT OF NEW JERSEY

3

4 -----x

5 IN RE JOHNSON & JOHNSON) MDL No.
6 TALCUM POWDER PRODUCTS) 16-2738 (FLW)(LHG)

7 MARKETING SALES PRACTICES

8 AND PRODUCTS LIABILITY

9 LITIGATION

11 THIS DOCUMENT RELATES TO

12 ALL CASES

15 VOLUME III
16 UNPAGED 30(b)(6) DEPOSITION OF DEFENDANT

PERSONAL CARE PRODUCTS COUNCIL

17 by and through its Designated Representative.

18 LINDA LORETTA Ph.D.

10 WASHINGTON, D. C.

20 TUESDAY OCTOBER 2 2018

31 0:01 A M

22

2

2

25 Rapporto di Lazio A - Todd

1 Q Mm-hmm. Now, the decision that is made
2 by an CI -- a CIR expert panel, what weight does
3 that have with the FDA?

4 MR. LOCKE: Objection to form and beyond
5 the scope.

6 THE WITNESS: I think FDA has
7 consistently said that they take into account CIR
8 conclusions. It's one piece of evidence.

9 BY MR. MEADOWS:

10 Q Okay. But they don't -- the FDA does
11 not adopt a CIR finding, does it?

12 A That's true.

13 Q In fact, the FDA has specifically said
14 that, correct?

15 A They have.

16 Q Okay. I want to look at Exhibit 91.
17 (Exhibit No. 91 was marked for
18 identification.)

19 BY MR. MEADOWS:

20 Q And this Exhibit 91 is from
21 PCPC-MDL-44971.

22 Do you recognize that document?

23 A I don't think so.

24 Q Okay. It does appear to come from the
25 PCPC files; is that right?